The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin
- PMID: 37327650
- DOI: 10.1016/j.preghy.2023.06.001
The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin
Abstract
Objectives: To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106).
Methodology: PE prevalence according to gestational age (GA) and the prevalence ratio (PR) between PE and prematurity, small for gestational age (SGA), and fetal death were calculated in patients assisted during 2015 and 2016.
Results: PE occurred in 373(10.75%) of 3468 investigated cases, where PE < 37 weeks was of 2.79% and PE greater than 37 weeks was of 7.95%. A total of 413 (11.9%) prematurity cases, 320 SGA (9.22%), and 50 fetal deaths (1.44%) occurred. In the PE group, 97 premature newborns (PR 0.90) and 51 SGA (PR 1.16) were born, and two fetal deaths occurred (PR 7.46). Concerning PE < 37 weeks, 27 SGA cases (PR 1.42) and two fetal deaths (PR 2.62) were observed. Regarding PE greater than 37 weeks, 24 SGA (PR 1.09) were born, and no fetal deaths were observed. Our findings were compared to previously published results.
Conclusions: PE was significantly associated with SGA newborns, especially premature PE. Prescribing aspirin for PE prophylaxis based only on clinical risk factors in a real-life scenario does not appear to be effective but resulted in a PE screening and prophylaxis protocol review and update at ME/UFRJ.
Keywords: Aspirin; Fetal death; Fetal growth restriction; Preeclampsia; Premature Infant.
Copyright © 2023. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Preeclampsia: Prevalence and perinatal repercussions in a University Hospital in Rio de Janeiro, Brazil.Pregnancy Hypertens. 2016 Oct;6(4):253-255. doi: 10.1016/j.preghy.2016.08.229. Epub 2016 Aug 12. Pregnancy Hypertens. 2016. PMID: 27939461
-
Maternal metabolic syndrome, preeclampsia, and small for gestational age infancy.Am J Obstet Gynecol. 2015 Sep;213(3):370.e1-7. doi: 10.1016/j.ajog.2015.05.045. Epub 2015 May 22. Am J Obstet Gynecol. 2015. PMID: 26008179
-
Comparison of risk factors for gestational hypertension and preeclampsia in Japanese singleton pregnancies.J Obstet Gynaecol Res. 2013 Feb;39(2):492-9. doi: 10.1111/j.1447-0756.2012.01990.x. Epub 2012 Sep 25. J Obstet Gynaecol Res. 2013. PMID: 23002807
-
Combined Anticoagulant Therapy for Prevention of Preeclampsia and Small for Gestational Age Neonates: A Systematic Review and Meta-analysis.Am J Perinatol. 2023 Dec;40(16):1745-1764. doi: 10.1055/a-1785-9032. Epub 2022 Mar 2. Am J Perinatol. 2023. PMID: 35235957
-
Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis.Am J Obstet Gynecol. 2022 Feb;226(2S):S1126-S1144.e17. doi: 10.1016/j.ajog.2020.11.006. Epub 2021 Apr 20. Am J Obstet Gynecol. 2022. PMID: 34301348
Cited by
-
Performance of the first-trimester Fetal Medicine Foundation competing risks model for preeclampsia prediction: an external validation study in Brazil.AJOG Glob Rep. 2024 Mar 29;4(2):100346. doi: 10.1016/j.xagr.2024.100346. eCollection 2024 May. AJOG Glob Rep. 2024. PMID: 38694483 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials